TY  - JOUR
AU  - Faehling, Martin
AU  - Fallscheer, Sabine
AU  - Schmiederer, Julia
AU  - Sträter, Jörn
AU  - Christopoulos, Petros
AU  - Lengerke, Claudia
AU  - Seifarth, Harald
TI  - Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation.
JO  - Lung cancer
VL  - 209
SN  - 0169-5002
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-02224
SP  - 108803
PY  - 2025
AB  - NSCLC with mutations of the KRAS or EGFR gene is associated with a high risk of brain metastases (BRA). There are few data on the prevalence and pattern of BRA and on survival in unselected KRAS or EGFR patients.This real-world analysis (KOMPASS-study) included 326 NSCLC patients with stage IV adenocarcinoma and either KRAS mutation (n = 90), EGFR mutation (n = 87), or no known driver mutation (n = 149). Prevalence, number, and size of BRA, and the effect of BRA on overall survival (OS) were analyzed.The prevalence of BRA was higher in KRAS patients (40 
KW  - CNS metastases (Other)
KW  - EGFR (Other)
KW  - Exon 21 (Other)
KW  - G12C (Other)
KW  - KRAS (Other)
KW  - Lung cancer (Other)
KW  - Number of brain metastases (Other)
KW  - Overall survival (Other)
KW  - Real world data (Other)
KW  - Size (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41151358
DO  - DOI:10.1016/j.lungcan.2025.108803
UR  - https://inrepo02.dkfz.de/record/305554
ER  -